BRPI0717822A2 - Composto, processo de fabricação de composto da fórmula i, composição farmacêutica, método de tratamento e/ou profilaxia de doenças que são associadas à modulação de receptores de cb2 e uso de composto. - Google Patents
Composto, processo de fabricação de composto da fórmula i, composição farmacêutica, método de tratamento e/ou profilaxia de doenças que são associadas à modulação de receptores de cb2 e uso de composto.Info
- Publication number
- BRPI0717822A2 BRPI0717822A2 BRPI0717822-0A2A BRPI0717822A BRPI0717822A2 BR PI0717822 A2 BRPI0717822 A2 BR PI0717822A2 BR PI0717822 A BRPI0717822 A BR PI0717822A BR PI0717822 A2 BRPI0717822 A2 BR PI0717822A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- prophylaxy
- receptors
- diseases
- modulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06121749 | 2006-10-04 | ||
PCT/EP2007/060090 WO2008040649A2 (en) | 2006-10-04 | 2007-09-24 | Pyrazine-2-carboxamide derivatives as cb2 receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0717822A2 true BRPI0717822A2 (pt) | 2013-11-12 |
Family
ID=39166552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0717822-0A2A BRPI0717822A2 (pt) | 2006-10-04 | 2007-09-24 | Composto, processo de fabricação de composto da fórmula i, composição farmacêutica, método de tratamento e/ou profilaxia de doenças que são associadas à modulação de receptores de cb2 e uso de composto. |
Country Status (18)
Country | Link |
---|---|
US (1) | US7691863B2 (pt) |
EP (1) | EP2076499B1 (pt) |
JP (1) | JP5064506B2 (pt) |
KR (1) | KR101114704B1 (pt) |
CN (1) | CN101522644B (pt) |
AR (1) | AR063101A1 (pt) |
AT (1) | ATE467622T1 (pt) |
AU (1) | AU2007304363B2 (pt) |
BR (1) | BRPI0717822A2 (pt) |
CA (1) | CA2664621A1 (pt) |
CL (1) | CL2007002834A1 (pt) |
DE (1) | DE602007006531D1 (pt) |
ES (1) | ES2344128T3 (pt) |
IL (1) | IL197763A0 (pt) |
MX (1) | MX2009003316A (pt) |
PE (1) | PE20080855A1 (pt) |
TW (1) | TW200825065A (pt) |
WO (1) | WO2008040649A2 (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7629346B2 (en) * | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
BRPI0717845A2 (pt) * | 2006-10-04 | 2015-06-16 | Hoffmann La Roche | Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos |
US8088920B2 (en) | 2008-03-31 | 2012-01-03 | Hoffmann-La Roche Inc. | 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents |
US7897621B2 (en) | 2008-03-31 | 2011-03-01 | Hoffmann-La Roche Inc. | 2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents |
US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
WO2012031817A1 (en) | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
US9403808B2 (en) * | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
ES2621958T3 (es) * | 2012-12-07 | 2017-07-05 | F. Hoffmann-La Roche Ag | Derivados de pirazina como agonistas receptores de CB2 |
KR20150091080A (ko) * | 2012-12-07 | 2015-08-07 | 에프. 호프만-라 로슈 아게 | Cb2 작용제로서 유용한 피리딘-2-아마이드 |
JP6426618B2 (ja) * | 2012-12-07 | 2018-11-21 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 新規なピリジン誘導体 |
MY179412A (en) * | 2012-12-07 | 2020-11-05 | Hoffmann La Roche | Pyridine-2-amides useful as cb2 agonists |
EA030032B1 (ru) * | 2014-04-04 | 2018-06-29 | Ф. Хоффманн-Ля Рош Аг | 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов |
SG10202110874TA (en) | 2016-06-07 | 2021-11-29 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
EA201992253A1 (ru) | 2017-03-23 | 2020-03-31 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
CN109384734B (zh) * | 2017-08-14 | 2023-04-11 | 上海科胜药物研发有限公司 | 一种塞尔西帕中间体的制备方法 |
CN112074513A (zh) * | 2018-06-27 | 2020-12-11 | 豪夫迈·罗氏有限公司 | 作为优先大麻素2激动剂的吡啶和吡嗪衍生物 |
EP3814329B1 (en) * | 2018-06-27 | 2024-01-17 | F. Hoffmann-La Roche AG | Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
WO2023082145A1 (en) * | 2021-11-11 | 2023-05-19 | 4B Technologies (Suzhou) Limited | Intermediate compound of quinoxaline and preparation process thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5738778A (en) * | 1980-08-18 | 1982-03-03 | Kyowa Gas Chem Ind Co Ltd | Novel cyanopyrazine derivative |
UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
GB0222493D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
JP4960085B2 (ja) * | 2003-03-19 | 2012-06-27 | エクセリクシス, インク. | Tie−2モジュレータと使用方法 |
US20060135523A1 (en) * | 2003-06-18 | 2006-06-22 | Astrazeneca Ab | 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator |
US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
GB0402357D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
DK1868999T3 (da) | 2005-04-06 | 2009-08-17 | Hoffmann La Roche | Pyridin-3-carboxamidderivater som omvendte CB1-agonister |
US7629346B2 (en) * | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
-
2007
- 2007-09-24 BR BRPI0717822-0A2A patent/BRPI0717822A2/pt not_active IP Right Cessation
- 2007-09-24 JP JP2009530841A patent/JP5064506B2/ja not_active Expired - Fee Related
- 2007-09-24 KR KR1020097008997A patent/KR101114704B1/ko not_active IP Right Cessation
- 2007-09-24 WO PCT/EP2007/060090 patent/WO2008040649A2/en active Application Filing
- 2007-09-24 US US11/903,581 patent/US7691863B2/en not_active Expired - Fee Related
- 2007-09-24 CN CN2007800372430A patent/CN101522644B/zh not_active Expired - Fee Related
- 2007-09-24 ES ES07820497T patent/ES2344128T3/es active Active
- 2007-09-24 DE DE602007006531T patent/DE602007006531D1/de active Active
- 2007-09-24 MX MX2009003316A patent/MX2009003316A/es active IP Right Grant
- 2007-09-24 CA CA002664621A patent/CA2664621A1/en not_active Abandoned
- 2007-09-24 EP EP07820497A patent/EP2076499B1/en not_active Not-in-force
- 2007-09-24 AU AU2007304363A patent/AU2007304363B2/en not_active Ceased
- 2007-09-24 AT AT07820497T patent/ATE467622T1/de active
- 2007-10-02 TW TW096136934A patent/TW200825065A/zh unknown
- 2007-10-02 AR ARP070104363A patent/AR063101A1/es unknown
- 2007-10-02 CL CL200702834A patent/CL2007002834A1/es unknown
- 2007-10-03 PE PE2007001334A patent/PE20080855A1/es not_active Application Discontinuation
-
2009
- 2009-03-23 IL IL197763A patent/IL197763A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2007304363A1 (en) | 2008-04-10 |
JP2010505788A (ja) | 2010-02-25 |
CA2664621A1 (en) | 2008-04-10 |
MX2009003316A (es) | 2009-04-09 |
EP2076499B1 (en) | 2010-05-12 |
US7691863B2 (en) | 2010-04-06 |
ATE467622T1 (de) | 2010-05-15 |
KR101114704B1 (ko) | 2012-03-14 |
KR20090084842A (ko) | 2009-08-05 |
WO2008040649A2 (en) | 2008-04-10 |
CN101522644B (zh) | 2013-04-24 |
AR063101A1 (es) | 2008-12-30 |
CN101522644A (zh) | 2009-09-02 |
CL2007002834A1 (es) | 2008-05-16 |
TW200825065A (en) | 2008-06-16 |
AU2007304363B2 (en) | 2013-01-17 |
EP2076499A2 (en) | 2009-07-08 |
US20080085905A1 (en) | 2008-04-10 |
WO2008040649A3 (en) | 2008-05-29 |
IL197763A0 (en) | 2009-12-24 |
JP5064506B2 (ja) | 2012-10-31 |
DE602007006531D1 (de) | 2010-06-24 |
PE20080855A1 (es) | 2008-06-28 |
ES2344128T3 (es) | 2010-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0717822A2 (pt) | Composto, processo de fabricação de composto da fórmula i, composição farmacêutica, método de tratamento e/ou profilaxia de doenças que são associadas à modulação de receptores de cb2 e uso de composto. | |
DK1984357T3 (da) | 2,4-pyrimidindiaminforbindelser til behandling eller forebyggelse af autoimmunsygdomme | |
BRPI0814593A2 (pt) | Composto, composição farmacêutica que o contém e uso do composto. | |
WO2007095638A3 (en) | Boron-containing small molecules as anti-inflammatory agents | |
BRPI0811712A2 (pt) | "composto, processo de preparação de um composto e composição farmacéutica". | |
CL2007002641A1 (es) | Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias. | |
BRPI0718339A2 (pt) | Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina | |
DE602006010132D1 (de) | Zwischenprodukte für die Herstellung von Trans-5-Chlor-2-Methyl-2,3,3a,12b-Tetrahydro-1h-DibenzÄ2,3:6,7ÜOxepinoÄ4,5-cÜPyrrol | |
EA200900781A1 (ru) | 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды | |
BRPI0716703A2 (pt) | "composiÇço, fluidos funcionais e processo de preparaÇço de uma composiÇço" | |
BRPI0818533A2 (pt) | composto, composição farmacêutica, e, processo para a preparação de um composto | |
BRPI0813341A2 (pt) | " uso de compostos, composições curáveis, e, uso de composições curáveis ". | |
BRPI0922742A2 (pt) | adesivo ou selante, processo para preparar um adesivo ou selante, e, uso do adesivo ou selante. | |
BRPI0717753A2 (pt) | Método de tratamento ou redução do risco de uma doença causada por protozoários, e, composição. | |
BRPI0717695A2 (pt) | "composição, uso de uma compsição e processo de preparação de uma composição" | |
BRPI0919918A2 (pt) | Composto de vanilina e de etilvanilina, processo de preparação do mesmo, composição, e, aplicação do composto. | |
BRPI1013396A2 (pt) | composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto. | |
EA201000258A1 (ru) | Новые гербициды | |
DE502007005902D1 (de) | -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate | |
BRPI0713031B8 (pt) | composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos | |
DK1879580T3 (da) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolinderivater som lægemidler til behandling af infertilitet | |
BRPI0720323A2 (pt) | composto, método de tratamento, composição farmacêutica e uso do composto | |
BRPI0909566A2 (pt) | Linhagem de h. Polymorpha recombinante, processo de elaboração de etanol que compreende o cultivo da linhagem de h. Polymorpha recombinante e ácido nucleico recombinante | |
ITRM20050179A1 (it) | Composizione impiegabile per il trattamento delle patologie paradontali. | |
BRPI0718999A2 (pt) | Pirazois substituídos, composições que os contêm, processo de produção e utilização |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |